Skip to main content
Clinical Trials/EUCTR2017-000632-34-FI
EUCTR2017-000632-34-FI
Active, not recruiting
Phase 1

Handling oxygenation targets in adults with acute hypoxaemic respiratory failure in the intensive care unit: A randomised clinical trial of a lower versus a higher oxygenation target - Handling Oxygenation Targets in the Intensive Care Unit (HOT-ICU)

Department of Anaesthesia and Intensive Care Medicine, Aalborg University Hospital0 sites2,928 target enrollmentFebruary 6, 2018

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Department of Anaesthesia and Intensive Care Medicine, Aalborg University Hospital
Enrollment
2928
Status
Active, not recruiting
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 6, 2018
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Department of Anaesthesia and Intensive Care Medicine, Aalborg University Hospital

Eligibility Criteria

Inclusion Criteria

  • \- Acutely admitted to the intensive care unit AND
  • \- Aged \= 18 years AND
  • \- Receive supplemental oxygen with a flow of at least 10 L per minute in an open system or at least an fraction of inspired oxygen of 0\.50 in a closed system, including invasive ventilation, non\-invasive ventilation or continuous positive airway pressure AND
  • \- Are expected to receive oxygen administration for at least 24 hours in the ICU AND
  • \- Have an arterial line in place
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 1312
  • F.1\.3 Elderly (\>\=65 years) yes

Exclusion Criteria

  • \- Cannot be randomised within twelve hours after present ICU admission
  • \- Chronic mechanical ventilation for any reason
  • \- Use of home oxygen
  • \- Previous treatment with bleomycin
  • \- Organ transplant during current hospital admission
  • \- Withdrawal from active therapy or brain death deemed imminent
  • \- Fertile woman with positive urine human gonadotropin (hCG) or
  • plasma\-hCG
  • \- Carbon monoxide poisoning
  • \- Cyanide poisoning

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 4
Handling oxygenation targets in adults with acute hypoxaemic respiratory failure in the intensive care unit: A randomised clinical trial of a lower versus a higher oxygenation target
NL-OMON44557niversitair Medisch Centrum Groningen100
Active, not recruiting
Phase 1
Oxygen supplementation in patients with acute pulmonary failure admitted to the intensive care unit: A clinical trial of two seperate levels of oxygen supplementation during treatment in the intensive care unitAddendum: Trial extension including only COVID-19 patientsAcute hypoxaemic respiratory failure in patients admitted to the intensive care unitAddendum: Acute hypoxaemic respiratory failure in patients admitted to the intensive care unit with COVID-19MedDRA version: 21.1Level: PTClassification code 10001053Term: Acute respiratory failureSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 21.1Level: PTClassification code 10022519Term: Intensive careSystem Organ Class: 10042613 - Surgical and medical proceduresTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2017-000632-34-DKDepartment of Anaesthesia and Intensive Care Medicine, Aalborg University Hospital3,708
Not yet recruiting
Phase 3
To find out the required level of Oxygen for respiratory care of premature babies at the time of delivery and to check its effect on babys development.
CTRI/2017/05/008517The University of Sydney represented by and acting through the NHMRC Clinical Trials Centre1,200
Recruiting
Not Applicable
Airway oxygen concentration with high flow nasal oxyge
ACTRN12618001256268Christchurch public hospital10
Completed
Not Applicable
Oxygen therapy for treating patients with residual sleep apnoea following upper airway surgery
ACTRN12617001361392Monash Health20